DexCom, Inc. (DXCM) is among the top 10 healthcare equipment stocks recommended by hedge funds. Analyst William Plovanic reduced the price target from $99 to $95 on February 13 while maintaining a Buy rating.

Plovanic highlighted DexCom’s focus on glucose sensor leadership, with the 15-day G7 expected to drive margins. Baird analyst Jeff Johnson reaffirmed an Outperform rating and raised the price target to $87, citing favorable factors from the fourth quarter results.

DexCom (DXCM) sells continuous glucose monitoring systems to manage diabetes. Products include DexCom G6 and G7, Share, Real-Time API, and ONE. While DXCM is a solid investment, other AI stocks may offer better upside potential and less downside risk.

For more healthcare and industrial stock insights, visit Insider Monkey. No disclosures mentioned in the article.

Read more at Yahoo Finance: DexCom, Inc. (DXCM) Continues to Focus on Glucose Sensors Leadership